LYSAKARE

This brand name is authorized in Austria, Estonia, France, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Poland, United Kingdom

Active ingredients

The drug LYSAKARE contains a combination of these active pharmaceutical ingredients (APIs):

1 Arginine UNII F7LTH1E20Y - ARGININE HYDROCHLORIDE

Arginine is an essential amino acid that is physiologically active in the L-form. It is commonly found as a component of total parenteral nutrition. Read about Arginine

2 Lysine UNII JNJ23Q2COM - LYSINE HYDROCHLORIDE

Read about Lysine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LYSAKARE Solution for infusion	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V03AF11		V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment
Discover more medicines within V03AF11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1800032
Country: FR	Base de données publique des médicaments	Identifier(s): 65395602
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 386102
Country: HK	Department of Health Drug Office	Identifier(s): 66931
Country: IT	Agenzia del Farmaco	Identifier(s): 048100010
Country: JP	医薬品医療機器総合機構	Identifier(s): 3253416A1020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088319
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100424790